Do analysts recommend OPTX or NAUT?

Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 78.57%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Nautilus Biotechnology (NAUT) Competitors

$2.24 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.04 (+1.83%)

As of 06/12/2026 07:49 PM Eastern

Compare

NAUT vs. EYPT, TRNS, FEIM, CTKB, and OPTX

Should you buy Nautilus Biotechnology stock or one of its competitors? MarketBeat compares Nautilus Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nautilus Biotechnology include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), and Syntec Optics (OPTX). These companies are all part of the "measuring and control equipment" industry.

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Nautilus Biotechnology (NASDAQ:NAUT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Nautilus Biotechnology presently has a consensus price target of $4.00, suggesting a potential upside of 78.57%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, suggesting a potential upside of 144.05%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Nautilus Biotechnology has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Eyepoint Pharmaceuticals	$31.37M	34.82	-$231.96M	-$3.50	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Nautilus Biotechnology's return on equity of -35.04% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Nautilus Biotechnology has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Eyepoint Pharmaceuticals	Positive

Summary

Eyepoint Pharmaceuticals beats Nautilus Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Transcat?

Transcat (NASDAQ:TRNS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Transcat has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Transcat presently has a consensus price target of $105.33, indicating a potential upside of 15.42%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 78.57%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.3% of Transcat shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Transcat has a net margin of 1.62% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 5.84% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

In the previous week, Transcat and Transcat both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.87 beat Transcat's score of 1.08 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Transcat	Positive
Nautilus Biotechnology	Very Positive

Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.57	$5.38M	$0.58	157.34
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Summary

Transcat beats Nautilus Biotechnology on 11 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Frequency Electronics?

Nautilus Biotechnology (NASDAQ:NAUT) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Frequency Electronics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Frequency Electronics and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.87 beat Frequency Electronics' score of 0.81 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Frequency Electronics	Positive

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Frequency Electronics has a net margin of 10.78% compared to Nautilus Biotechnology's net margin of 0.00%. Frequency Electronics' return on equity of 12.69% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Frequency Electronics	10.78%	12.69%	7.84%

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 78.57%. Frequency Electronics has a consensus price target of $43.67, suggesting a potential downside of 41.99%. Given Nautilus Biotechnology's higher possible upside, research analysts clearly believe Nautilus Biotechnology is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Frequency Electronics has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Frequency Electronics	$69.81M	10.61	$23.69M	$0.75	100.37

Nautilus Biotechnology has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Summary

Frequency Electronics beats Nautilus Biotechnology on 11 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Cytek Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Nautilus Biotechnology has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$204.17M	2.50	-$66.54M	-$0.57	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Cytek Biosciences presently has a consensus target price of $5.69, indicating a potential upside of 43.62%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 78.57%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cytek Biosciences had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Cytek Biosciences and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.87 beat Cytek Biosciences' score of 0.62 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Nautilus Biotechnology	Very Positive

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Cytek Biosciences' return on equity of -10.07% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Summary

Cytek Biosciences beats Nautilus Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

50.7% of Nautilus Biotechnology shares are held by institutional investors. 0.8% of Syntec Optics shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Syntec Optics had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Syntec Optics and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.87 beat Syntec Optics' score of 0.19 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Syntec Optics	Neutral
Nautilus Biotechnology	Very Positive

Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 78.57%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Syntec Optics has a beta of -0.82, indicating that its share price is 182% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Syntec Optics has higher revenue and earnings than Nautilus Biotechnology. Syntec Optics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$28.08M	19.01	-$1.79M	-$0.08	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Syntec Optics' net margin of -10.95%. Syntec Optics' return on equity of -30.86% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Summary

Nautilus Biotechnology beats Syntec Optics on 9 of the 15 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$284.66M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-4.87	20.00	24.00	24.42
Price / Sales	N/A	306.82	514.36	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.81	8.32	10.54	6.82
Net Income	-$59M	$23.94M	$3.57B	$337.56M
7 Day Performance	-3.86%	1.84%	0.60%	1.17%
1 Month Performance	-10.76%	-0.04%	1.56%	3.16%
1 Year Performance	219.54%	44.82%	25.42%	30.58%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	3.2019 of 5 stars	$2.24 flat	$4.00 +78.6%	+219.5%	$284.66M	N/A	N/A	130	Positive News Gap Up
EYPT Eyepoint Pharmaceuticals	2.7486 of 5 stars	$11.77 +2.8%	$31.80 +170.2%	+44.3%	$959.98M	$31.37M	N/A	120	Positive News High Trading Volume
TRNS Transcat	2.8184 of 5 stars	$90.00 +0.3%	$105.33 +17.0%	+15.3%	$838.51M	$331.88M	155.18	1,413	Positive News
FEIM Frequency Electronics	1.2779 of 5 stars	$66.94 -4.3%	$43.67 -34.8%	+308.5%	$688.54M	$69.81M	89.25	200	Gap Up
CTKB Cytek Biosciences	2.2992 of 5 stars	$4.13 +2.2%	$5.69 +37.7%	+23.0%	$521.74M	$201.49M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Summary

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Do analysts rate NAUT or EYPT?

Which has stronger earnings and valuation, NAUT or EYPT?

Is NAUT or EYPT more profitable?

Which has more volatility & risk, NAUT or EYPT?

Do institutionals & insiders have more ownership in NAUT or EYPT?

Does the media favor NAUT or EYPT?

Summary

How does Nautilus Biotechnology compare to Transcat?

Which has more volatility & risk, TRNS or NAUT?

Do analysts rate TRNS or NAUT?

Do institutionals & insiders believe in TRNS or NAUT?

Is TRNS or NAUT more profitable?

Does the media refer more to TRNS or NAUT?

Which has preferable valuation and earnings, TRNS or NAUT?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Does the media favor NAUT or FEIM?

Do insiders & institutionals believe in NAUT or FEIM?

Is NAUT or FEIM more profitable?

Do analysts rate NAUT or FEIM?

Which has stronger valuation and earnings, NAUT or FEIM?

Which has more risk and volatility, NAUT or FEIM?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Which has more risk & volatility, CTKB or NAUT?

Which has stronger valuation & earnings, CTKB or NAUT?

Do analysts prefer CTKB or NAUT?

Does the media refer more to CTKB or NAUT?

Do insiders & institutionals believe in CTKB or NAUT?

Is CTKB or NAUT more profitable?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Do insiders & institutionals believe in OPTX or NAUT?

Does the media refer more to OPTX or NAUT?

Do analysts recommend OPTX or NAUT?

Which has more volatility & risk, OPTX or NAUT?

Which has better valuation & earnings, OPTX or NAUT?

Is OPTX or NAUT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools